Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
CONCLUSION AND RELEVANCE: This MA provided encouraging results on pamrevlumab efficacy in slowing the decline in FVC compared with pirfenidone and nintedanib. Actually, in phase 3, it could become a potential IPF treatment.
PMID: 33054319 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Di Martino E, Provenzani A, Vitulo P, Polidori P Tags: Ann Pharmacother Source Type: research
More News: Databases & Libraries | Drugs & Pharmacology | International Medicine & Public Health | Study | WHO